China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...

A rare condition called Eosinophilic Fasciitis caused a 42-year-old engineer severe pain and stiffness. Doctors identified ...

Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...

OPEN The FTSE 100 was expected to open 57 points higher (+0.6%) ahead of the bell on Monday, after finishing Friday's session 0.2% higher at a record closing price of 9,951.14.

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

His elbow moved normally, his thighs were supple, his shoulder pain had disappeared, and the skin tightening had eased ...

The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.

GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...